Skip to main content

INFLAMACION ASOCIADA AL DAÑO METABOLICO CRONICO EN LA DIABETES TIPO 2 Y SUS COMPLICACIONES

SAF2015-65267-R

•
Funding agency name Ministerio de Economía y Competitividad
Funding agency acronym MINECO
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos I+D+i Retos de Investigación
Call year 2015
State Plan 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Management unit Dirección General de Investigación Científica y Técnica
Beneficiary centre AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 36
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Transcription factor NRF2 as a therapeutic target for chronic diseases: A systems medicine approach

  • Cuadrado, Antonio
  • Manda, Gina
  • Hassan, Ahmed
  • Alcaraz, María José
  • Barbas, Coral
  • Daiber, Andreas
  • Ghezzi, Pietro
  • León, Rafael
  • López, Manuela G.
  • Oliva Miguel, Baldomero
  • Pajares, Marta
  • Rojo, Ana I.
  • Robledinos Antón, Natalia
  • Valverde, Ángela María
  • Guney, Emre
  • Schmidt, Harald H.H.W.
Systems medicine has a mechanism-based rather than a symptom- or organ-based approach to disease and identifies therapeutic targets in a nonhypothesis-driven manner. In this work, we apply this to transcription factor nuclear factor (erythroid-derived 2)-like 2 (NRF2) by cross-validating its position in a protein-protein interaction network (the NRF2 interactome) functionally linked to cytoprotection in low-grade stress, chronic inflammation, metabolic alterations, and reactive oxygen species formation. Multiscale network analysis of these molecular profiles suggests alterations of NRF2 expression and activity as a common mechanism in a subnetwork of diseases (the NRF2 diseasome). This network joins apparently heterogeneous phenotypes such as autoimmune, respiratory, digestive, cardiovascular, metabolic, and neurodegenerative diseases, along with cancer. Importantly, this approach matches and confirms in silico several applications for NRF2-modulating drugs validated in vivo at different phases of clinical development. Pharmacologically, their profile is as diverse as electrophilic dimethyl fumarate, synthetic triterpenoids like bardoxolone methyl and sulforaphane, protein-protein or DNA-protein interaction inhibitors, and even registered drugs such as metformin and statins, which activate NRF2 and may be repurposed for indications within the NRF2 cluster of disease phenotypes. Thus, NRF2 represents one of the first targets fully embraced by classic and systems medicine approaches to facilitate both drug development and drug repurposing by focusing on a set of disease phenotypes that appear to be mechanistically linked. The resulting NRF2 drugome may therefore rapidly advance several surprising clinical options for this subset of chronic diseases., This work was supported by Grants SAF2015-71304-REDT, SAF2016-76520-R, SAF2013-4874R, SAF2015-65267-R, and BIO2014-57518 of the Spanish Ministry of Economy and Competiveness; PII4/00372 from the Health Institute Carlos III; PROMETEOII/2014/071 of Generalitat Valenciana; P_37_732/2016 REDBRAIN of the European Regional Development Fund; Competitiveness Operational Program 2014-2020; and the ERC Advanced Grant RadMed 294683 and COST action 15120 OpenMultiMed (H.H.H.W.S.). M.P. is the recipient of a FPU fellowship of Autonomous University of Madrid. E.G. is supported by a European-cofunded Beatriu de Pinos fellowship. R.L. is supproted by the Miguel Servet II fellow (CPII16/00014).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Transcription Factor NRF2 as a Therapeutic Target for Chronic Diseases: A Systems Medicine Approach

  • Cuadrado, Antonio
  • Manda, Gina
  • Hassan, Ahmed
  • ALCARAZ TORMO, Mª JOSE
  • Barbas, Coral
  • Daiber, Andreas
  • Ghezzi, Pietro
  • León, Rafael
  • Lopez, Manuela G.
  • Oliva, Baldo
  • Pajares, Marta
  • Rojo, Ana I.
  • Robledinos-Antón, Natalia
  • Valverde, Ángela M.
  • Guney, Emre
This work was supported by Grants SAF2015-71304-REDT, SAF2016-76520-R, SAF2013-4874R, SAF2015-65267-R, and BIO2014-57518 of the Spanish Ministry of Economy and Competiveness; PII4/00372 from the Health Institute Carlos III; PROMETEOII/2014/071 of Generalitat Valenciana; P_37_732/2016 REDBRAIN of the European Regional Development Fund; Competitiveness Operational Program 2014-2020; and the ERC Advanced Grant RadMed 294683 and COST action 15120 OpenMultiMed (H.H.H.W.S.). M.P. is the recipient of a FPU fellowship of Autonomous University of Madrid. E.G. is supported by a European-cofunded Beatriu de Pinos fellowship. R.L. is supproted by the Miguel Servet II fellow (CPII16/00014)
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

A novel glucagon-like peptide 1/glucagon receptor dual agonist improves steatohepatitis and liver regeneration in mice

  • Valdecantos, M. P.
  • Pardo, Virginia
  • Ruiz, Laura
  • Castro-Sánchez, Luis
  • Fernández-Millán, Elisa
  • García-Monzón, Carmelo
  • Arroba, Ana I.
  • González-Rodríguez, Águeda
  • Escrivá, Fernando
  • Álvarez, Carmen
  • Grimsby, J.
  • Rondinone, Cristina M.
  • Valverde, Ángela M.
Because nonalcoholic steatohepatitis (NASH) is associated with impaired liver regeneration, we investigated the effects of G49, a dual glucagon-like peptide-1/glucagon receptor agonist, on NASH and hepatic regeneration. C57Bl/6 mice fed chow or a methionine and choline–deficient (MCD) diet for 1 week were divided into 4 groups: control (chow diet), MCD diet, chow diet plus G49, and M+G49 (MCD diet plus G49). Mice fed a high-fat diet (HFD) for 10 weeks were divided into groups: HFD and H+G49 (HFD plus G49). Following 2 (MCD groups) or 3 (HFD groups) weeks of treatment with G49, partial hepatectomy (PH) was performed, and all mice were maintained on the same treatment schedule for 2 additional weeks. Analysis of liver function, hepatic regeneration, and comprehensive genomic and metabolic profiling were conducted. NASH was ameliorated in the M+G49 group, manifested by reduced inflammation, steatosis, oxidative stress, and apoptosis and increased mitochondrial biogenesis. G49 treatment was also associated with replenishment of intrahepatic glucose due to enhanced gluconeogenesis and reduced glucose use through the pentose phosphate cycle and oxidative metabolism. Following PH, G49 treatment increased survival, restored the cytokine-mediated priming phase, and enhanced the proliferative capacity and hepatic regeneration ratio in mice on the MCD diet. NASH markers remained decreased in M+G49 mice after PH, and glucose use was shifted to the pentose phosphate cycle and oxidative metabolism. G49 administered immediately after PH was also effective at alleviating the pathological changes induced by the MCD diet. Benefits in terms of liver regeneration were also found in mice fed HFD and treated with G49. Conclusion: Dual-acting glucagon-like peptide-1/glucagon receptor agonists such as G49 represent a novel therapeutic approach for patients with NASH and particularly those requiring PH. (Hepatology 2017;65:950-968)., Supported by MINECO (SAF2015-65267-R) cofunded by the Fondos Europeos de Desarrollo Regional de la Unión Europea (FEDER), CIBERdem (ISCIII, Spain), INFLAMES (PIE-14/00045 (PIE-14/00045 ISCIII, Spain)), and the European Foundation for the Study of Diabetes (to A.M.V.). Financial support was also received from MedImmune (MA-416191) as a research agreement with the Instituto de Investigaciones Biomedicas Alberto Sols., Peer reviewed, Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

p38α regulates actin cytoskeleton and cytokinesis in hepatocytes during development and aging

  • Tormos, Ana M.
  • Rius-Pérez, Sergio
  • Jorques, María
  • Rada, Patricia
  • Ramírez, Lorena
  • Valverde, Ángela M.
  • Nebreda, Ángel R.
  • Sastre, Juan
  • Taléns-Visconti, Raquel
[Background]: Hepatocyte poliploidization is an age-dependent process, being cytokinesis failure the main mechanism of polyploid hepatocyte formation. Our aim was to study the role of p38α MAPK in the regulation of actin cytoskeleton and cytokinesis in hepatocytes during development and aging. [Methods]: Wild type and p38α liver-specific knock out mice at different ages (after weaning, adults and old) were used. [Results]: We show that p38α MAPK deficiency induces actin disassembly upon aging and also cytokinesis failure leading to enhanced binucleation. Although the steady state levels of cyclin D1 in wild type and p38α knock out old livers remained unaffected, cyclin B1- a marker for G2/M transition- was significantly overexpressed in p38α knock out mice. Our findings suggest that hepatocytes do enter into S phase but they do not complete cell division upon p38α deficiency leading to cytokinesis failure and binucleation. Moreover, old liver-specific p38α MAPK knock out mice exhibited reduced F-actin polymerization and a dramatic loss of actin cytoskeleton. This was associated with abnormal hyperactivation of RhoA and Cdc42 GTPases. Long-term p38α deficiency drives to inactivation of HSP27, which seems to account for the impairment in actin cytoskeleton as Hsp27-silencing decreased the number and length of actin filaments in isolated hepatocytes. [Conclusions]: p38α MAPK is essential for actin dynamics with age in hepatocytes., AMT was recipient of a fellowship from the Ministry of Economy and Competitiveness. PR was recipient of a postdoctoral contract Juan de la Cierva (MINECO, Spain). This work was supported by Grants SAF 2015-71208-R with FEDER funds and CSD-2007-00020 from the Spanish Ministry of Economy and Competitiveness (MINECO, Spain, http://www.mineco.gob.es/portal/site/mineco/) and GV PROMETEO II 2014-056 from Generalitat Valenciana to JS and RTV, and by Grant SAF 2015-65267-R (MINECO/FEDER) and by Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM, ISCIII, Spain) to AMV. ARN was funded by grants from MINECO (BFU2010-17850) and the European Commission (ERC 294665)., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Targeting inflammation in the retina: a new therapeutic approach in diabetic retinopathy, El tratamiento de la inflamacion en la retina: una nueva estrategia terapéutica en la retinopatía diabética

  • Arroba, Ana I.
  • Valverde, Ángela M.
[EN]: Retinal diseases linked to inflammation, including diabetic retinopathy (DR), are often accompanied by resident macrophage/microglial cells activation. During DR, there are substantial changes in the polarization status of the microglia from the M2 (anti-inflammatory) to the M1 (pro-inflammatory) stage. However, the dynamics between M1 and M2 polarization of microglia during DR has not been investigated and it might be therapeutically useful. In this study, we have characterized the evolution of microglia polarizarion during the early stages of DR in the retina of diabetic db/db mice. Moreover, we have analyzed microglia polarization in response to pro-(bacterial lipopolysaccharide; LPS) or anti-(IL4/IL13 cytokines or the bicyclic nojirimycin derivative (1R)-1-dodecylsulfinyl-5N,6O-oxomethylidenenojirimycin (RDS-ONJ)) inflammatory stimuli. For this goal, we have performed in vitro experiments in Bv-2 murine microglial cells as well as ex vivo experiments in retinal explants from db/db mice. Treatment of Bv-2 cells with LPS together with IL4/IL13 or R-DS-ONJ switched the M1 response towards M2. In retinal explants from db/db mice, R-DS-ONJ induced a M2 response. In conclusion, the modulation of microglia polarization dynamics towards a M2 status at early stages of DR offers novel therapeutic interventions., [ES]: Las enfermedades retinianas, entre las que se encuentra la retinopatía diabética (RD), están vinculadas a un contexto inflamatorio en el cual existe una activación de los macrófagos residentes en la retina (microglia). Durante la retinopatía diabética se producen cambios de polarización de la microglia, definiéndose éstos como transiciones entre el estado M1 (proinflamatorio) y el estado M2 (anti-inflamatorio), estando aún por determinar los tiempos de aparición y actuación de la microglia en cada uno de ellos. La identificación espacio-temporal de la transición de la microglía de un estado a otro podría constituir una potente herramienta clínica para diferentes abordajes terapéuticos. En este trabajo se ha caracterizado el estado de polarización de la microgía en la retina durante las primeras fases de la RD en el modelo de ratón diabético db/db. Además, se ha estudiado la polarización de la microglia en presencia de estímulos pro-inflamatorios (lipopolisacárido bacteriano; LPS) o anti-inflamatorios (citoquinas IL4/IL13 o un compuesto natural derivado de la casternospermina, R-DS-ONJ). Para ello, se ha realizado un abordaje in vitro utilizando la línea celular de microglia murina Bv-2 y un abordaje ex vivo con explantes de retinas procedentes de ratones diabéticos db/db. El tratamiento de las células Bv-2 con LPS en combinación con IL4/IL13 o alternativamente con el compuesto R-DS-ONJ indujo la transición en la polarización de la microglia desde el estado proinflamatorio M1, inducido por el LPS, al estado antiinflamatorio M2. En los explantes de retinas de ratones db/db, el compuesto R-DS-ONJ indujo la respuesta M2 disminuyendo la respuesta M1. En conclusión, la polarización de la microglia hacía un estado M2 durante los estadíos tempranos de la RD ofrece una nueva ventana terapéutica de actuación., This work was supported by grants from the Spanish Ministry of Economy and Competitivity (SAF2015-65267-R and SAF2012-33283), Comunidad de Madrid S2010/BMD-2423 and S2010/BMD2439, Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERdem, Instituto Carlos III, Spain), European Union (EUROCONDOR (FP7 HEALTH.2011.2.4.3.1.))., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Somatostatin protects photoreceptor cells against high glucose–induced apoptosis

  • Arroba, Ana I.
  • Cazzoni, Daniele
  • Hernández, Cristina
  • Simó, Rafael
  • Valverde, Ángela M.
This is an open-access article distributed under the terms of the Creative Commons Attribution License.-- et al., [Purpose]: Many cellular and molecular studies in experimental animals and early retinal function tests in patients with diabetic retinopathy (DR) have shown that retinal neurodegeneration is an early event in the pathogenesis of the disease. Somatostatin (SST) is one of the most important neuroprotective factors synthesized by the retina: SST levels are decreased in parallel to retinal neurodegeneration in early stages of DR. In this study, we characterized the induction of apoptosis (programmed cell death) in a 661W photoreceptor-like cell line cultured under high glucose (HG) conditions and the effect of SST. [Methods]: A 661W photoreceptor-like cell line and retinal explants from 10-week-old male C57BL/6 mice were cultured under HG conditions and treated with SST. [Results]: Hyperglycemia significantly reduced the cellular viability by increasing the percentage of apoptotic cells, and this effect was ameliorated by SST (p˂0.05). Activation of caspase-8 by hyperglycemia was found in the 661W cells and retinal explants and decreased in the presence of SST (p˂0.05). Moreover, we detected activation of calpain-2 associated with hyperglycemia-induced cell death, as well as increased protein tyrosine phosphatase 1B (PTP1B) protein levels; both had a pattern of cleavage that was absent in the presence of SST (p˂0.05). Treatment of the 661W cells and retinal explants with SST for 24 h increased the phosphorylation of type 1 insulin-like growth factor receptor (IGF-IR; tyrosine 1165/1166) and protein kinase B (Akt; serine 473), suggesting this survival signaling is activated in the neuroretina by SST (p˂0.05). [Conclusions]: This study has provided new mechanistic insights first into the involvement of calpain-2 and PTP1B in the loss of cell survival and increased caspase-8-dependent apoptosis induced by hyperglycemia in photoreceptor cells and second, on the protective effect of SST against apoptosis by the enhancement of IGF-IR-mediated Akt phosphorylation., This work was supported by grants from European Union: (EUROCONDOR project grant agreement number 278,040) and FP7-People-2012-CIG (grant agreement number 333,594), Spanish Ministry of Economy and Competitivity: SAF2012-35562 and SAF2015-65267R cofunded by the Fondos Europeos de Desarrollo Regional de la Unión Europea [FEDER] and Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERdem)., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Rapamycin negatively impacts insulin signaling, glucose uptake and uncoupling protein-1 in brown adipocytes

  • García-Casarrubios, Ester
  • Arroba, Ana I.
  • Pescador, Nuria
  • García, Laura
  • Cadenas, Susana
  • Carvalho, Eugenia
  • Obregón, María Jesús
  • Valverde, Ángela M.
New onset diabetes after transplantation (NODAT) is a metabolic disorder that affects 40% of patients on immunosuppressive agent (IA) treatment, such as rapamycin (also known as sirolimus). IAs negatively modulate insulin action in peripheral tissues including skeletal muscle, liver and white fat. However, the effects of IAs on insulin sensitivity and thermogenesis in brown adipose tissue (BAT) have not been investigated. We have analyzed the impact of rapamycin on insulin signaling, thermogenic gene-expression and mitochondrial respiration in BAT. Treatment of brown adipocytes with rapamycin for 16 h significantly decreased insulin receptor substrate 1 (IRS1) protein expression and insulin-mediated protein kinase B (Akt) phosphorylation. Consequently, both insulin-induced glucose transporter 4 (GLUT4) translocation to the plasma membrane and glucose uptake were decreased. Early activation of the N-terminal Janus activated kinase (JNK) was also observed, thereby increasing IRS1 Ser 307 phosphorylation. These effects of rapamycin on insulin signaling in brown adipocytes were partly prevented by a JNK inhibitor. In vivo treatment of rats with rapamycin for three weeks abolished insulin-mediated Akt phosphorylation in BAT. Rapamycin also inhibited norepinephrine (NE)-induced lipolysis, the expression of peroxisome proliferator-activated receptor γ coactivator 1α (PGC-1α) and uncoupling protein (UCP)-1 in brown adipocytes. Importantly, basal mitochondrial respiration, proton leak and maximal respiratory capacity were significantly decreased in brown adipocytes treated with rapamycin. In conclusion, we demonstrate, for the first time the important role of brown adipocytes as target cells of rapamycin, suggesting that insulin resistance in BAT might play a major role in NODAT development., This work was supported by Ministerio de Economía y Competitividad: (SAF2015-65267-R to AMV, SAF2012-32491 to MJO, SAF2013-45887-R to LH, and SAF2014-52223-C2-1-R to DS) that were cofunded by the Fondos Europeos de Desarrollo Regional de la Unión Europea [FEDER], Spain, Instituto de Salud Carlos III (FIS PI15-00448 to SC and INFLAMES PIE14/00045 to AMV), Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERdem, ISCIII, Spain) to AMV, Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBERobn-Grant CB06/03/0001) to DS and S2010/BMD-2423 (Comunidad de Madrid, Spain) to AMV and MJO and S2010/BMD-2402 to SC and 2014SGR465 (Generalitat de Catalunya, Spain) to DS. CdM was supported by the Albert Reynold Grant travel fellowship from the European Foundation for the Study of Diabetes. EC and FR were funded by FEDER through the Operational Programme Competitiveness Factors - COMPETE and by FCT - Foundation for Science and TechnologyPTDC/SAU-OSM/104124/2008 and strategic project UID/NEU/04539/2013., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Modulation of microglia polarization dynamics during diabetic retinopathy in db/db mice

  • Arroba, Ana I.
  • García-Ramírez, Marta
  • Cazzoni, Daniele
  • García Fernández, José Manuel
  • Valverde, Ángela M.
Retinal diseases linked to inflammation are often accompanied by macrophage/microglial cells activation. However, the dynamics between M1 (pro-inflammatory) and M2 (anti-inflammatory) polarization of microglia during diabetic retinopathy (DR) has not been investigated and it might be therapeutically useful. We assessed microglia polarization in retinas from db/db mice and human diabetic donors and also the microgliamediated anti-inflammatory effects of the bicyclic nojirimycin derivative (1R)-1-dodecylsulfinyl-5N,6Ooxomethylidenenojirimycin (R-DS-ONJ). Visual function in mice was evaluated by electroretinogram (ERG). Expression of pro- and anti-inflammatory markers in the retina was analyzed by immunofluorescence, Western-blot and quantitative real-time PCR. Lipopolysaccharide (LPS)-mediated polarization profile was studied in Bv.2 microglial cells in the absence or presence of anti-inflammatory cytokines (IL4/IL13) or R-DSONJ. At 5weeks of age, reduced ERG amplitude values of rod and mixed waves were detected in db/db compared to db/+ mice that correlated with elevated circulating endotoxemia and pro-inflammatory cytokines. At this early stage of DR, the marker of activated microglia Iba-1 co-localized with the M2 marker arginase-1 in the retina. Conversely, in retinas from 8 weeks old db/db mice Iba-1-colocalizedwith active caspase-1, a key component of the inflammasome, reflecting an opposite pattern of microglia polarization. Markers of activated microglia were detected in retinas of diabetic donors. Treatment of Bv.2 cells with LPS and IL4/IL13 or R-DS-ONJ switched the M1 response towards M2. In retinal explants from db/db mice, R-DS-ONJ induced a M2 response. In conclusion, the modulation of microglia polarization dynamics towards aM2 status at early stages of DR offers novel therapeutic interventions., This work was supported by grants from the Spanish Ministry of Economy and Competitivity: SAF2015-65267-R(MINECO/RETOS), SAF2012-35562 and SAF2013-44021-R, the Junta de Andalucía (FQM2012-1467), Comunidad de Madrid S2010/BMD-2423 and S2010/BMD2439, Instituto de Salud Carlos III Grant number PI13-02098, Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERdem, Instituto Carlos III, Spain), Red de Patología Ocular Prevalente y Crónica (OFTARED, Instituto de Salud Carlos III, Spain), European Union (EUROCONDOR (FP7 HEALTH.2011.2.4.3.1.), and the European Union Seventh Framework Programme (FP7-People-2012-CIG) grant agreement number 333594., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Heme-regulated eIF2α kinase modulates hepatic FGF21 and is activated by PPARβ/δ deficiency

  • Zarei, Mohammad
  • Pardo, Virginia
  • González-Rodríguez, Águeda
  • Valverde, Ángela M.
  • Villaroya, Francesc
  • Vázquez-Carrera, Manuel
Fibroblast growth factor 21 (FGF21), a peptide hormone with pleiotropic effects on carbohydrate and lipid metabolism, is considered a target for the treatment of diabetes. We investigated the role of peroxisome proliferator-activated receptor (PPAR) b/d deficiency in hepatic FGF21 regulation. Increased Fgf21 expression was observed in the livers of PPARb/d-null mice and in mouse primary hepatocytes when this receptor was knocked down by small interfering RNA (siRNA). Increased Fgf21 was associated with enhanced protein levels in the heme-regulated eukaryotic translation initiation factor 2a (eIF2a) kinase (HRI). This increase caused enhanced levels of phosphorylated eIF2a and activating transcription factor (ATF) 4, which is essential for Fgf21-induced expression. siRNA analysis demonstrated that HRI regulates Fgf21 expression in primary hepatocytes. Enhanced Fgf21 expression attenuated tunicamycin-induced endoplasmic reticulum stress, as demonstrated by using a neutralizing antibody against FGF21. Of note, increased Fgf21 expression in mice fed a high-fat diet or hepatocytes exposed to palmitate was accompanied by reduced PPARb/d and activation of the HRI-eIF2α-ATF4 pathway. Moreover, pharmacological activation of HRI increased Fgf21 expression and reduced lipid-induced hepatic steatosis and glucose intolerance, but these effects were not observed in Fgf21-null mice. Overall, these findings suggest that HRI is a potential target for regulating hepatic FGF21 levels., This study was partly supported by funds from the Spanish Ministry of the Economy and Competitiveness (SAF2015-65267-R to Á.M.V., SAF2014-55725 to F.V., and SAF2012-30708 and SAF2015-64146-R to M.V.-C.) and the European Union European Regional Development Fund. CIBERDEM and CIBEROBN are Instituto de Salud Carlos III Health Institute projects. T.Q.-L. is supported by a CONACyT (National Council for Science and Technology in Mexico) PhD scholarship. W.W. is supported by start-up grants from the Lee Kong Chian School of Medicine, Nanyang Technological University, and by the Région Midi-Pyrénées, France., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Friedelane-type triterpenoids as selective anti-inflammatory agents by regulation of differential signaling pathways in LPS-stimulated macrophages

  • Villar-Lorenzo, Andrea
  • Ardiles, Alejandro E.
  • Arroba, Ana I.
  • Pardo, Virginia
  • López-Collazo, Eduardo
  • Bazzocchi, Isabel L.
  • González-Rodríguez, Águeda
  • Valverde, Ángela M.
A series of 31 pentacyclic triterpenoids isolated from the root barks of Celastrus vulcanicola and Maytenus jelskii were tested for cytotoxicity and inhibitory activity against lipopolysaccharide (LPS)-induced nitric oxide (NO) production in RAW 264.7 macrophages. Compounds 18 (C18) and 25 (C25) exhibited significant inhibition of LPS-induced NO release at 50 and 25 μM concentrations, respectively, and decreased mRNAs of pro-inflammatory cytokines. At the molecular level, C18 neither inhibited LPS-mediated phosphorylation of mitogen activated protein kinases (MAPKs) nor nuclear translocation of nuclear factor kappa beta (NFκB). Instead, C18 enhanced and prolonged nuclear translocation of nuclear factor-erythroid 2-related factor 2 (Nrf2) and increased the expression of its target genes including hemeoxigenase 1 (HO1). C25 efficiently inhibited LPS-mediated phosphorylation of JNK, p38 and ERK, without affecting NFκB or Nrf2 signaling pathways. Both compounds reduced LPS-mediated processing of caspase-1 and the cleavage of interleukin 1β (IL1β) proform, reflecting their ability to target the inflammasome. C25 also counteracted LPS effects on iNOS expression and pro-inflammatory cytokines mRNA levels in Bv-2 microglial cells. The anti-inflammatory effect of both compounds was also assessed in human macrophages. Our results suggest that triterpenoids C18 and C25 possess anti-inflammatory effects, which may be therapeutically relevant for diseases linked to inflammation., This work was supported by grants SAF2015-65267-R/FEDER (Ministerio de Economía y Competitividad, Spain), Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERdem, Instituto de Salud Carlos III, Spain), PIE14/00045-INFLAMES (Instituto de Salud Carlos III, Spain) to A.M.V., CP14/00181 (Instituto de Salud Carlos III, Spain) to A. G-R., Fundación CajaCanarias SALUCAN03 and SAF2015-65113-C2-1-R/FEDER to I.L.B. and Fondo de Investigación Sanitaria and Fondos FEDER to E. L-C. Dr. A. E. thanks FONDECYT Postdoctoral 3160414 and CONICYT-Chile for the fellowship., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Cyclooxygenase-2 expression in hepatocytes attenuates non-alcoholic steatohepatitis and liver fibrosis in mice

  • Motiño, Omar
  • Agra, Noelia
  • Brea, Rocío
  • Domínguez-Moreno, Marina
  • García-Monzón, Carmelo
  • Carnovale, Cristina E.
  • Boscá, Lisardo
  • Casado, Marta
  • Mayoral, Rafael
  • Valdecantos, M. P.
  • Valverde, Ángela M.
  • Francés, Daniel E.
  • Martín-Sanz, Paloma
Cyclooxygenase-2 (COX-2) is involved in different liver diseases but little is known about the significance of COX-2 in the development and progression of non-alcoholic steatohepatitis (NASH). This study was designed to elucidate the role of COX-2 expression in hepatocytes in the pathogenesis of steatohepatitis and hepatic fibrosis. In the present work, hepatocyte-specific COX-2 transgenic mice (hCOX-2-Tg) and their wild-type (Wt) littermates were either fed methionine-and-choline deficient (MCD) diet to establish an experimental non-alcoholic steatohepatitis (NASH) model or injected with carbon tetrachloride (CCl) to induce liver fibrosis. In our animal model, hCOX-2-Tg mice fed MCD diet showed lower grades of steatosis, ballooning and inflammation than Wt mice, in part by reduced recruitment and infiltration of hepatic macrophages, with a corresponding decrease in serum levels of pro-inflammatory cytokines. Furthermore, hCOX-2-Tg mice showed a significant attenuation of the MCD diet-induced increase in oxidative stress and hepatic apoptosis observed in Wt mice. Even more, hCOX-2-Tg mice treated with CCl had significantly lower stages of fibrosis and less hepatic content of collagen, hydroxyproline and pro-fibrogenic markers than Wt controls. Collectively, our data indicates that constitutive hepatocyte COX-2 expression ameliorates NASH and liver fibrosis development in mice by reducing inflammation, oxidative stress and apoptosis and by modulating activation of hepatic stellate cells, respectively, suggesting a possible protective role for COX-2 induction in NASH/NAFLD progression., This work was supported by Financing Program for short stays abroad for Assistant Researchers (CONICET-Argentina) (2618/13) and ANPCyT-PICT2383-2012 to D.F.; SAF2012-39732 (MINECO, Spain) and CIBERehd (ISCIII, Spain) (CB06/04/1069) to M.C.; SAF2014-52492 (MINECO, Spain) to L.B.; S2010/BMD-2378 (Comunidad de Madrid, CAM) to L.B. and P.M.S.; RD12/0042/0019 (ISCIII, Spain) and CIBERehd (ISCIII, Spain) to L.B. and P.M.S.; SAF-2015-65267-R (MINECO/FEDER), S2010/BMD-2423 (Comunidad de Madrid, CAM), EFSD and Amylin Paul Langerhans Grant and CIBERdem (ISCIII, Spain) to A.M.V.; PI13/01299 (ISCIII, Spain) to C.G-M.; SAF2013-43713-R (MINECO, Spain) to P.M.S., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Carnitine palmitoyltransferase 1 increases lipolysis, UCP1 protein expression and mitochondrial activity in brown adipocytes

  • Calderón‐Domínguez, María
  • García-Casarrubios, Ester
  • Obregón, María Jesús
  • Valverde, Ángela M.
  • Herrero, Laura
This is an open access article distributed under the terms of the Creative Commons Attribution License.-- et al., The discovery of active brown adipose tissue (BAT) in adult humans and the fact that it is reduced in obese and diabetic patients have put a spotlight on this tissue as a key player in obesity-induced metabolic disorders. BAT regulates energy expenditure through thermogenesis; therefore, harnessing its thermogenic fat-burning power is an attractive therapeutic approach. We aimed to enhance BAT thermogenesis by increasing its fatty acid oxidation (FAO) rate. Thus, we expressed carnitine palmitoyltransferase 1AM (CPT1AM), a permanently active mutant form of CPT1A (the rate-limiting enzyme in FAO), in a rat brown adipocyte (rBA) cell line through adenoviral infection. We found that CPT1AM-expressing rBA have increased FAO, lipolysis, UCP1 protein levels and mitochondrial activity. Additionally, enhanced FAO reduced the palmitate-induced increase in triglyceride content and the expression of obese and inflammatory markers. Thus, CPT1AM-expressing rBA had enhanced fat-burning capacity and improved lipid-induced derangements. This indicates that CPT1AM-mediated increase in brown adipocytes FAO may be a new approach to the treatment of obesity-induced disorders., This work was supported by the Ministry of Spain - MINECO (SAF2013-45887-R to LH, SAF2014-52223-C2-1-R to DS and SAF-2015-65267-R to AMV that were cofunded by the Fondos Europeos de Desarrollo Regional de la Unión Europea [FEDER], SAF2012-32491 to MJO, SAF2013-40987R to AZ, and a doctoral fellowship to JFM), the Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN) (Grant CB06/03/0001 to DS), the Centro de Investigación Biomédica en red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), the Generalitat de Catalunya (2014SGR465 to DS, and 2014SGR48 to AZ), the Comunidad de Madrid (S2010/BMD-2423 to MJO and AMV), INTERREG IV-B-SUDOE-FEDER (DIOMED, SOE1/P1/E178) to AZ, and the European Foundation for the Study of Diabetes (EFSD)/Janssen-Rising Star and L’Oréal-UNESCO “For Women in Science” research fellowships to LH. AZ is a recipient of ICREA-Academia (Generalitat de Catalunya) and MW is a recipient of the Ciência sem Fronteiras-CNPq fellowship (237976/2012-9)., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Autophagy resolves early retinal inflammation in Igf1-deficient mice

  • Arroba, Ana I.
  • Rodriguez-de la Rosa, Lourdes
  • Murillo-Cuesta, Silvia
  • Vaquero-Villanueva, Laura
  • Hurlé, Juan M.
  • Varela-Nieto, Isabel
  • Valverde, Ángela M.
Insulin-like growth factor-1 (IGF-1) is a growth factor with differentiating, anti-apoptotic and metabolic functions in the periphery, and anti-inflammatory properties in the nervous system. Mice that have mutations in the Igf1 gene, rendering the gene product inactive (Igf1), present with age-related visual loss accompanied by structural alterations in the first synapses of the retinal pathway. Recent advances have revealed a crucial role of autophagy in immunity and inflammation. Keeping in mind this close relationship, we aimed to decipher these processes in the context of the defects that occur during ageing in the retina of Igf1 mice. Tnfa and Il1bmRNAs, and phosphorylation of JNK and p38 MAPK were elevated in the retinas of 6- and 12-month old Igf1 mice compared to those in agematched Igf1 controls. In 6-month-old Igf1 retinas, increased mRNAlevelsofthe autophagy mediators Becn1, Atg9, Atg5 and Atg4, decreased p62 (also known as SQSTM1) protein expression together with an increased LC3-II:LC3-I ratio reflected active autophagic flux. However, in retinas from 12-month-old Igf1 mice, Nlrp3 mRNA, processing of the IL1β pro-form and immunostaining of active caspase-1 were elevated compared to those in age-matched Igf1 controls, suggesting activation of the inflammasome. This effect concurred with accumulation of autophagosomes and decreased autophagic flux in the retina. Microglia localization and status of activation in the retinas of 12-month-old Igf1 and Igf1 mice, analyzed by immunostaining of Cd11b and Iba-1, showed a specific distribution pattern in the outer plexiform layer (OPL), inner plexiform layer (IPL) and inner nuclear layer (INL), and revealed an increased number of activated microglia cells in the retina of 12-month-old blind Igf1 mice. Moreover, reactive gliosis was exclusively detected inthe retinas from 12-month-old blind Igf1 mice. In conclusion, this study provides new evidence in a mouse model of IGF-1 deficiency that autophagy is an adaptive response that might confer protection against persistent inflammation in the retina during ageing., This work was supported by grants from the Spanish Ministerio de Economia y Competitividad [grant numbers SAF2015-65267-R MINECO/FEDER (to A.M.V.) and SAF2014-53979-R (I.V.-N.)]; Instituto de Salud Carlos III [grant number INFLAMES, PIE14/00045]; Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERdem, Instituto Carlos III, Spain); and European Union and Marie Curie Industry-Academia Partnerships and Pathways (IAPP), TARGEAR [grant number FP7 PEOPLE 2013 IAPP-612261, http://cordis.europa.eu/project/rcn/110205_en.html (to I.V.-N.)]., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

PGC-1α downregulation in the steatotic liver enhances ischemia-reperfusion injury and impairs ischemic preconditioning

  • Sánchez-Ramos, Cristina
  • Prieto, Ignacio
  • Tierrez, Albert
  • Laso, Javier
  • Valdecantos, M. P.
  • Bartrons, Ramón
  • Roselló-Catafau, Joan
  • Monsalve, María
[Aims]: Liver steatosis is associated with mitochondrial dysfunction and elevated reactive oxygen species (ROS) levels together with enhanced sensitivity to ischemia-reperfusion (IR) injury and limited response to preconditioning protocols. Here, we sought to determine whether the downregulation in the steatotic liver of peroxisome proliferator-activated receptor γ co-activator 1α (PGC-1α), a master regulator of mitochondrial metabolism and ROS that is known to play a role in liver metabolic control, could be responsible for the sensitivity of the steatotic liver to ischemic damage. [Results]: PGC-1α was induced in normal liver after exposure to an IR protocol, which was concomitant with an increase in the levels of antioxidant proteins. By contrast, its induction was severely blunted in the steatotic liver, resulting in a modest induction of antioxidant proteins. Livers of PGC-1α-/- mice on a chow diet were normal, but they exhibited an enhanced sensitivity to IR injury and also a lack of response to ischemic preconditioning (IPC), a phenotype that recapitulated the features of the steatotic liver in terms of liver damage, although the inflammatory response differed between both models. Utilizing an in vitro model of IPC, we found that PGC-1α expression was downregulated in hepatic cells cultured at 1% O2; whereas it was induced after reoxygenation (3% O2), and it was responsible for the recovery of antioxidant gene expression after the ischemic period. [Innovation & Conclusion]: PGC-1α plays an important role in the protection against IR injury in the liver, which is likely associated with its capacity to induce antioxidant gene expression., This work was supported by grants from the Spanish ‘‘Ministerio de Economía y Competitividad’’ (MINECO) and FEDER funds (Grant Nos. SAF2012-37693, SAF2015-63904-R [MINECO/FEDER], CSD 2007-00020 & SAF2015-71521-REDC, SAF2015-65267-R), the ‘‘Comunidad Autónoma de Madrid’’ (grant No. S2010/BMD-2361), and CIBER (ISCIII)., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Increased FGF21 in brown adipose tissue of tyrosine hydroxylase heterozygous mice: implications for cold adaptation, Increased FGF21 expression in BAT of TH heterozygous mice

  • Vázquez Pérez, Patricia
  • Hernández-Sánchez, Catalina
  • Escalona-Garrido, Carmen
  • Pereira, Laura
  • Contreras, Cristina
  • López, Miguel
  • Balsinde, Jesús
  • Pablo, Flora de
  • Valverde, Ángela M.
Tyrosine hydroxylase (TH) catalyzes the first step in catecholamines synthesis. We studied the impact of reduced TH in brown adipose tissue (BAT) activation. In adult heterozygous (Th+/-) mice, dopamine and noradrenaline (NA) content in BAT decreased after cold exposure. This reduced catecholaminergic response did not impair cold adaptation, since these mice induced uncoupling protein-1 (UCP1) and maintained BAT temperature to a similar extent than controls (Th+/+). Possible compensatory mechanisms implicated were studied. Prdm16 and Fgf21 expression, key genes in BAT activation, were elevated in Th+/- mice at thermoneutrality from day 18.5 of embryonic life. Likewise, plasma FGF21 and liver Fgf21 mRNA were increased. Analysis of endoplasmic reticulum (ER) stress, a process that triggers elevations in FGF21, showed higher phospho-IRE1, phospho-JNK and CHOP in BAT of Th+/- mice at thermoneutrality. Also, increased lipolysis in BAT of coldexposure Th+/- mice was demonstrated by increased phosphorylation of hormone-sensitive lipase (HSL), as well as diacylglycerol (DAG) and free fatty acids (FFA) content. Overall, these results indicate that the mild effects of Th haploinsufficiency on BAT function are likely due to compensatory mechanisms involving elevations in Fgf21 and Prdm16 and through adaptive changes in the lipid profile., This work was supported by a Ministry of Science, Technology and Innovation grants BFU 2010-15868 to FdeP and CHS, SAF2015-73000-EXP and SAF2016-80883 to JB and SAF2015-65267-R to AMV. We also acknowledge grant INFLAMES (ISCIII PIE14/00045, co-funded by ERDF, “Investing in your future”) to AMV and Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas CIBERdem This is an initiative of the Instituto de Salud Carlos III (Madrid,Spain). We thank MICINN-CSIC and Fondo Social Europeo (FSE) for the JAE-DOC contract (2013 to PV) and CIBERdem contract (to PV 2016)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Differential effects of metformin glycinate and hydrochloride in glucose production, AMPK phosphorylation and insulin sensitivity in hepatocytes from non-diabetic and diabetic mice

  • Rada, Patricia
  • Mosquera, Alejandra
  • Muntané, Jordi
  • Ferrandiz, Francisco
  • Rodríguez-Mañas, Leocadio
  • Pablo, Flora de
  • González-Canudas, Jorge
  • Valverde, Ángela M.
The liver is a main target tissue of the biguanide metformin which activates AMP-activated protein kinase (AMPK). We previously reported that administration of metformin glycinate showed a greater decrease of glycated hemoglobin A1c than a placebo in patients with type 2 diabetes mellitus (T2DM). In this study, we compared the effects of metformin hydrochloride, the oral antidiabetic drug of first choice, with those of metformin glycinate in hepatocytes from non-diabetic and diabetic mice and humans. Both formulations were equally potent regard to the reduction of basal and glucagon-induced glucose production and mRNA levels of gluconeogenic enzymes (Pck1 and G6pc) in hepatocytes from C57/Bl6 mice and humans. On the contrary, phosphorylation of AMPK and its substrate acetyl CoA carboxylase (ACC) was faster in hepatocytes treated with metformin glycinate. Likewise, we found stronger reduction in hepatocytes from obese/diabetic db/db mice of glucagon-induced glucose output and more sustained AMPK phosphorylation after treatment with metformin glycinate. Importantly, insulin sensitization regarding phosphorylation of AKT (Ser473) was enhanced in hepatocytes from db/db mice or humans pretreated with metformin glycinate. In conclusion, our data indicate that metformin glycinate may be an alternative therapy against insulin resistance during obesity and/or T2DM., Financial support was received from Laboratorios Silanes S.A. de C.V. (Project reference 20159770) as a research agreement with the Instituto de Investigaciones Biomedicas Alberto Sols (CSIC). This work was also funded by grants SAF2015-65267-R (MINECO/FEDER), S2017/BMD-3684 MOIR2-CM (Comunidad de Madrid, Spain), CIBERdem (ISCIII, Spain), and H2020 Marie Sklodowska-Curie ITN-TREATMENT (Grant Agreement number 721236) (European Commission) to A.M.V. and IJCI-2014-19381 (MINECO/FEDER) to P.R and A.M.V., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

The sp2-iminosugar glycolipid 1-dodecylsulfonyl-5N,6O-oxomethylidenenojirimycin (DSO2-ONJ) as selective anti-inflammatory agent by modulation of hemeoxygenase-1 in Bv.2 microglial cells and retinal explants

  • Alcalde-Estévez, Elena
  • Arroba, Ana I.
  • Sánchez-Fernández, Elena M.
  • Ortiz-Mellet, Carmen
  • García Fernández, José Manuel
  • Masgrau, Laura
  • Valverde, Ángela M.
Neuroinflammation is an early event during diabetic retinopathy (DR) that impacts the dynamics of microglia polarization. Gliosis is a hallmark of DR and we have reported the beneficial effects of 1R-DSO-ONJ, a member of the sp2-iminosugar glycolipid (sp2-IGL) family, in targeting microglia and reducing gliosis in diabetic db/db mice. Herein, we analyzed the effect of DSO2-ONJ, another family compound incorporating a sulfone group that better mimics the phosphate group of phosphatidylinositol ether lipid analogues (PIAs), in Bv.2 microglial cells treated with bacterial lipopolysaccaride (LPS) and in retinal explants from db/db mice. In addition to decreasing iNOS and inflammasome activation, the anti-inflammatory effect of DSO2-ONJ was mediated by direct p38α MAPK activation. Computational docking experiments demonstrated that DSO2-ONJ binds to p38α MAPK at the same site where PIAs and the alkyl phospholipid perifosine activators do, suggesting similar mechanism of action. Moreover, treatment of microglial cells with DSO2-ONJ increased both heme-oxygenase (HO)-1 and Il10 expression regardless the presence of LPS. In retinal explants from db/db mice, DSO2-ONJ also induced HO-1 and reduced gliosis. Since IL-10-mediated induction of HO-1 expression is mediated by p38α MAPK activation, our results suggest that this molecular mechanism is involved in the anti-inflammatory effects of DSO2-ONJ in microglia., This work was supported by grants from the Spanish Ministry of Economy and Competitiveness: SAF2015-65267-R (MINECO/FEDER), SAF2016-76083-R (MINECO-FEDER), CTQ2015-64425-C2-1-R (MINECO-FEDER) and CTQ2014-53144-P and grants from the Spanish ISCIII (CIBERdem) and INFLAMES (ISCIII PIE14/00045, co-funded by ERDF, “Investing in your future”). We also acknowledge the European Union project H2020-MSCA-ITN TREATMENT Grant Agreement number: 721236. L.M. thanks the Universitat Autònoma de Barcelona-Banco Santander Program for financial support., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

SIRT1 controls acetaminophen hepatotoxicity by modulating inflammation and oxidative stress

  • Rada, Patricia
  • Pardo, Virginia
  • Mobasher, Maysa A.
  • García Martínez, Irma
  • Ruiz, Laura
  • González-Rodríguez, Águeda
  • Sánchez-Ramos, Cristina
  • Muntané, Jordi
  • Alemany, Susana
  • James, Laura P.
  • Simpson, Kenneth J.
  • Monsalve, María
  • Valdecantos, M. P.
  • Valverde, Ángela M.
ARS Open., [Aims]: Sirtuin 1 (SIRT1) is a key player in liver physiology and a therapeutic target against hepatic inflammation. We evaluated the role of SIRT1 in the proinflammatory context and oxidative stress during acetaminophen (APAP)-mediated hepatotoxicity., [Results]: SIRT1 protein levels decreased in human and mouse livers following APAP overdose. SIRT1-Tg mice maintained higher levels of SIRT1 on APAP injection than wild-type mice and were protected against hepatotoxicity by modulation of antioxidant systems and restrained inflammatory responses, with decreased oxidative stress, proinflammatory cytokine messenger RNA levels, nuclear factor kappa B (NFκB) signaling, and cell death. Mouse hepatocytes stimulated with conditioned medium of APAP-treated macrophages (APAP-CM) showed decreased SIRT1 levels; an effect mimicked by interleukin (IL)1β, an activator of NFκB. This negative modulation was abolished by neutralizing IL1β in APAP-CM or silencing p65-NFκB in hepatocytes. APAP-CM of macrophages from SIRT1-Tg mice failed to downregulate SIRT1 protein levels in hepatocytes. In vivo administration of the NFκB inhibitor BAY 11-7082 preserved SIRT1 levels and protected from APAP-mediated hepatotoxicity., [Inovation]: Our work evidenced the unique role of SIRT1 in APAP hepatoprotection by targeting oxidative stress and inflammation., [Conclusion]: SIRT1 protein levels are downregulated by IL1β/NFκB signaling in APAP hepatotoxicity, resulting in inflammation and oxidative stress. Thus, maintenance of SIRT1 during APAP overdose by inhibiting NFκB might be clinically relevant., [Rebound Track]: This work was rejected during standard peer review and rescued by Rebound Peer Review (Antioxid Redox Signal 16:293-296, 2012) with the following serving as open reviewers: Rafael de Cabo, Joaquim Ros, Kalervo Hiltunen, and Neil Kaplowitz. Antioxid. Redox Signal. 28, 1187-1208., This work was funded by SAF2015-65267-R (MINECO/FEDER), CIBERdem (ISCIII, Spain), and INFLAMES (ISCIII PIE14/00045, cofunded by ERDF, ‘‘Investing in your future’’) to A.M.V.; IJCI-2014-19381 (MINECO/FEDER) to P.R. and A.M.V.; SAF2014-52009-R (MINECO/FEDER) to S.A.; SAF2015-63904-R (MINECO/FEDER) to M.M.; CP14/00181 (ISCIII/FEDER) to A.G.-R.; and PI13/00021 (ISCIII/FEDER) to J.M. CIBERehd (ISCIII) to A.G.-R. and J.M.; Grant 37/371 from Al Jouf University to M.A.M. We also acknowledge H2020 Marie Sklodowska-Curie ITNTREATMENT (Grant Agreement No. 721236) (European Commission)., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Hepatic regulation of VLDL receptor by PPARβ/δ and FGF21 modulates non-alcoholic fatty liver disease

  • Zarei, Mohammad
  • Barroso, Emma
  • Palomer, Xavier
  • Dai, Jianli
  • Rada, Patricia
  • Quesada-López, Tania
  • Escolà-Gil, Joan Carles
  • Cedó, Lídia
  • Reza Zali, Mohammad
  • Molaei, Mahsa
  • Dabiri, Reza
  • Vázquez, Santiago
  • Pujol, Eugènia
  • Valverde, Ángela M.
  • Villarroya, Francesc
  • Liu, Yong
  • Wahli, Walter
  • Vázquez-Carrera, Manuel
[Objective] The very low-density lipoprotein receptor (VLDLR) plays an important role in the development of hepatic steatosis. In this study, we investigated the role of Peroxisome Proliferator-Activated Receptor (PPAR)b/d and fibroblast growth factor 21 (FGF21) in hepatic VLDLR regulation. [Methods] Studies were conducted in wild-type and Pparb/d-null mice, primary mouse hepatocytes, human Huh-7 hepatocytes, and liver biopsies from control subjects and patients with moderate and severe hepatic steatosis. [Results] Increased VLDLR levels were observed in liver of Pparb/d-null mice and in Pparb/d-knocked down mouse primary hepatocytes through mechanisms involving the heme-regulated eukaryotic translation initiation factor 2a (eIF2a) kinase (HRI), activating transcription factor (ATF) 4 and the oxidative stress-induced nuclear factor (erythroid-derived 2)-like 2 (Nrf2) pathways. Moreover, by using a neutralizing antibody against FGF21, Fgf21-null mice and by treating mice with recombinant FGF21, we show that FGF21 may protect against hepatic steatosis by attenuating endoplasmic reticulum (ER) stress-induced VLDLR upregulation. Finally, in liver biopsies from patients with moderate and severe hepatic steatosis, we observed an increase in VLDLR levels that was accompanied by a reduction in PPARb/d mRNA abundance and DNA-binding activity compared with control subjects. [Conclusions]: Overall, these findings provide new mechanisms by which PPARb/d and FGF21 regulate VLDLR levels and influence hepatic steatosis development., This study was partly supported by funds from the Spanish Ministry of the Economy and Competitiveness (SAF2015-64146-R to MVC, SAF2014-55725 to FV, and SAF2015-65267-R to AMV) and European Union ERDF funds. CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM) and CIBER Fisiopatologia de la Obesidad y Nutrición (CIBERobn) are Carlos III Health Institute projects. WW is supported by Start-Up Grants from the Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, and by the Région Midi-Pyrénées, France, and TQL is supported by a CONACyT (National Council for Science and Technology in Mexico) Ph.D. scholarship., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Protection against gamma-radiation injury by protein tyrosine phosphatase 1B

  • Mojena, Marina
  • Pimentel-Santillana, María
  • Povo-Retana, Adrián
  • Fernández-García, Victoria
  • González-Ramos, Silvia
  • Rada, Patricia
  • Tejedor, Alberto
  • Rico, Daniel
  • Martín-Sanz, Paloma
  • Valverde, Ángela M.
  • Boscá, Lisardo
Protein tyrosine phosphatase 1B (PTP1B) is widely expressed in mammalian tissues, in particular in immune cells, and plays a pleiotropic role in dephosphorylating many substrates. Moreover, PTP1B expression is enhanced in response to pro-inflammatory stimuli and to different cell stressors. Taking advantage of the use of mice deficient in PTP1B we have investigated the effect of γ-radiation in these animals and found enhanced lethality and decreased respiratory exchange ratio vs. the corresponding wild type animals. Using bone-marrow derived macrophages and mouse embryonic fibroblasts (MEFs) from wild-type and PTP1B-deficient mice, we observed a differential response to various cell stressors. PTP1B-deficient macrophages exhibited an enhanced response to γ-radiation, UV-light, LPS and S-nitroso-glutathione. Macrophages exposed to γ-radiation show DNA damage and fragmentation, increased ROS production, a lack in GSH elevation and enhanced acidic β-galactosidase activity. Interestingly, these differences were not observed in MEFs. Differential gene expression analysis of WT and KO macrophages revealed that the main pathways affected after irradiation were an up-regulation of protein secretion, TGF-β signaling and angiogenesis among other, and downregulation of Myc targets and Hedgehog signaling. These results demonstrate a key role for PTP1B in the protection against the cytotoxicity of irradiation in intact animal and in macrophages, which might be therapeutically relevant., This work was supported by grants SAF2017-82436R, SAF2016-75004R and SAF2015-65267 from MINIECO, S2017/BMD-3686 and BMD3684 from Comunidad de Madrid, Fundación Ramón Areces (2016/CIVP18A3864) and Cibercv, Ciberdem and Ciberehd (funded by the Instituto de Salud Carlos III and by Fondos FEDER). We also acknowledge H2020 Marie Sklodowska-Curie ITN-TREATMENT (Grant Agreement number 721236) (European Commission). P.R. was recipient a Juan de la Cierva postdoctoral contract from MINIECO (IJCI-2014-19381)., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

IGF-1, inflammation and retinal degeneration: A close network

  • Arroba, Ana I.
  • Campos-Caro, Antonio
  • Aguilar-Diosdado, Manuel
  • Valverde, Ángela M.
Retinal degenerative diseases are a group of heterogeneous diseases that include age-related macular degeneration (AMD), retinitis pigmentosa (RP), and diabetic retinopathy (DR). The progressive degeneration of the retinal neurons results in a severe deterioration of the visual function. Neuroinflammation is an early hallmark of many neurodegenerative disorders of the retina including AMD, RP and DR. Microglial cells, key components of the retinal immune defense system, are activated in retinal degenerative diseases. In the microglia the interplay between the proinflammatory/classically activated or antiinflammatory/alternatively activated phenotypes is a complex dynamic process that occurs during the course of disease due to the different environmental signals related to pathophysiological conditions. In this regard, an adequate transition from the proinflammatory to the anti-inflammatory response is necessary to counteract retinal neurodegeneration and its subsequent damage that leads to the loss of visual function. Insulin like-growth factor-1 (IGF-1) has been considered as a pleiotropic factor in the retina under health or disease conditions and several effects of IGF-1 in retinal immune modulation have been described. In this review, we provide recent insights of inflammation as a common feature of retinal diseases (AMD, RP and RD) highlighting the role of microglia, exosomes and IGF-1 in this process., The work of AIA and ÁMV has been funded by grants from European Union (project H2020-MSCA-ITN TREATMENT Grant Agreement number: 721236 and project EUROCONDOR FP7 Grant Agreement number 278040), grant from the Spanish Ministry of Economy and Competitiveness: SAF2015-65267-R (MINECO/FEDER) and grants from the Spanish ISCIII (CIBERdem) and INFLAMES (ISCIII PIE14/00045, co-funded by ERDF, Investing in your future)., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Contribución de congreso (ConferenceOutput)

Modulation of SIRT1 by IL-1β/NFκB signaling during Acetaminophen-induced hepatotoxicity

  • Rada, Patricia
  • Pardo, Virginia
  • Mobasher, Maysa A.
  • García Martínez, Irma
  • Ruiz, Laura
  • González-Rodríguez, Águeda
  • Sánchez-Ramos, Cristina
  • Muntané, Jordi
  • Alemany, Susana
  • Monsalve, María
  • Valdecantos, M. P.
  • Valverde, Ángela M.
Resumen del trabajo presentado al 5th Symposium on Biomedical Research: "Advances and Perspectives In Pharmacology, Drug Toxicity and Pharmacogenetics", celebrado en Madrid del 15 al 16 de marzo de 2018., [Introduction]: The liver is the main organ in charge of drug catabolism and also the major site susceptible to drug injury. Sirtuin 1 (SIRT1), a NAD+-dependent histone deacetylase, is a key player in liver physiology and a therapeutic target against hepatic inflammation. In this study, we evaluated the role of SIRT1 in the pro-inflammatory context and oxidative stress during acetaminophen (APAP)-mediated hepatotoxicity., [Material and Methods]: SIRT1 expression was analyzed in APAP-induced liver failure in humans and mice. Hepatotoxicity was assessed in wild-type and transgenic mice overexpressing SIRT1 (SIRT1 Tg) poisoned with APAP (300 mg/kg). Raw 264.7 and peritoneal macrophages were treated with APAP and conditioned medium (CM) was added to mouse hepatocytes. siRNA was used to reduce inflammatory mediators in hepatocytes., [Results]: SIRT1 protein levels decreased in human and mouse livers following APAP overdose. SIRT1-Tg mice maintained higher levels of SIRT1 upon APAP injection than wild-type mice and were protected against hepatotoxicity by modulation of antioxidant systems and restrained inflammatory responses, with decreased oxidative stress, pro-inflammatory cytokine mRNA levels, nuclear factor kappa B (NFκB) signaling, and cell death. Mouse hepatocytes stimulated with conditioned medium of APAP-treated macrophages (APAP-CM) showed decreased SIRT1 levels; an effect mimicked by interleukin 1β (IL1β), an activator of NFκB. This negative modulation was abolished by neutralizing IL1β in APAP-CM or silencing p65-NFκB in hepatocytes. APAP-CM of macrophages from SIRT1-Tg mice failed to downregulate SIRT1 protein levels in hepatocytes. In vivo administration of the NFκB inhibitor BAY 11-7082 preserved SIRT1 levels and protected from APAP-mediated hepatotoxicity., [Conclusion]: SIRT1 protein levels are downregulated by IL1β/NFκB signaling in APAP hepatotoxicity, resulting in inflammation and oxidative stress. Thus, maintenance of SIRT1 during APAP overdose by inhibiting NFκB might be clinically relevant. Our work evidenced the unique role of SIRT1 in APAP hepatoprotection by targeting oxidative stress and inflammation., This work was funded by SAF2015-65267-R (MINECO/FEDER), CIBERdem (ISCIII, Spain), INFLAMES (ISCIII PIE14/00045, co-funded by ERDF, “Investing in your future”) to A.M.V; IJCI-2014-19381 (MINECO/FEDER) to P.R and A.M.V; SAF2014-52009-R (MINECO/FEDER) to S.A; SAF2015-63904-R (MINECO/FEDER) to M.M.; CP14/00181 (ISCIII/FEDER) to A. G-R; PI13/00021 (ISCIII/FEDER) to J.M. CIBERehd (ISCIII, Spain) to A. G-R and J.M; Grant 37/371 from Al Jouf University (to M.A.M). We also acknowledge H2020 Marie Sklodowska-Curie ITN-TREATMENT (Grant Agreement number 721236) (European Commission)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Dual role of protein tyrosine phosphatase 1B in the progression and reversion of non-alcoholic steatohepatitis

  • González-Rodríguez, Águeda
  • Valdecantos, M. P.
  • Rada, Patricia
  • Addante, Annalisa
  • Barahona, Inés
  • Rey, Esther
  • Pardo, Virginia
  • Ruiz, Laura
  • Laiglesia, Laura M.
  • Moreno-Aliaga, María Jesús
  • García-Monzón, Carmelo
  • Sánchez, Aránzazu
  • Valverde, Ángela M.
[Objectives]: Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in Western countries. Protein tyrosine phosphatase 1B (PTP1B), a negative modulator of insulin and cytokine signaling, is a therapeutic target for type 2 diabetes and obesity. We investigated the impact of PTP1B deficiency during NAFLD, particularly in non-alcoholic steatohepatitis (NASH). [Methods]: NASH features were evaluated in livers from wild-type (PTP1BWT) and PTP1B-deficient (PTP1BKO) mice fed methionine/choline-deficient diet (MCD) for 8 weeks. A recovery model was established by replacing MCD to chow diet (CHD) for 2–7 days. Non-parenchymal liver cells (NPCs) were analyzed by flow cytometry. Oval cells markers were measured in human and mouse livers with NASH, and in oval cells from PTP1BWT and PTP1BKO mice. [Results]: PTP1BWT mice fed MCD for 8 weeks exhibited NASH, NPCs infiltration, and elevated Fgf21, Il6 and Il1b mRNAs. These parameters decreased after switching to CHD. PTP1B deficiency accelerated MCD-induced NASH. Conversely, after switching to CHD, PTP1BKO mice rapidly reverted NASH compared to PTP1BWT mice in parallel to the normalization of serum triglycerides (TG) levels. Among NPCs, a drop in cytotoxic natural killer T (NKT) subpopulation was detected in PTP1BKO livers during recovery, and in these conditions M2 macrophage markers were up-regulated. Oval cells markers (EpCAM and cytokeratin 19) significantly increased during NASH only in PTP1B-deficient livers. HGF-mediated signaling and proliferative capacity were enhanced in PTP1BKO oval cells. In NASH patients, oval cells markers were also elevated. [Conclusions]: PTP1B elicits a dual role in NASH progression and reversion. Additionally, our results support a new role for PTP1B in oval cell proliferation during NAFLD., This work was funded by SAF2015-65267-R (MINECO/FEDER), CIBERdem (ISCIII, Spain), INFLAMES (ISCIII PIE14/00045, co-funded by ERDF, “Investing in your future”) to A.M.V; IJCI-2014-19381 (MINECO/FEDER) to P.R and A.M.V; CP14/00181 and PI16/00823 (ISCIII/FEDER) and CIBERehd (ISCIII, Spain) to A.G-R; BFU2015-65937-R (MINECO/FEDER), 67-2015 (Department of Health, Navarra Government) and CIBERobn (ISCIII, Spain) to M.J.M; SAF2015-69145-R (MINECO/FEDER) to A.S. A.A. was recipient of a Marie Curie ESR contract from IT-LIVER (Marie Curie Action of the FP7-2012, grant agreement 316549). We also acknowledge the European Union, project H2020-MSCA-ITN TREATMENT Grant Agreement number: 721236., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Involvement of G protein-coupled receptor kinase 2 (GRK2) in the development of non-alcoholic steatosis and steatohepatitis in mice and humans

  • Cruces-Sande, Marta
  • Vila-Bedmar, Rocío
  • Arcones, Alba C.
  • González-Rodríguez, Águeda
  • Rada, Patricia
  • Gutiérrez-de-Juan, Virginia
  • Vargas-Castrillón, Javier
  • Iruzubieta, Paula
  • Sánchez-González, Cristina
  • Formentini, Laura
  • Crespo, Javier
  • García-Monzón, Carmelo
  • Martínez-Chantar, María Luz
  • Valverde, Ángela M.
  • Mayor Jr., Federico
  • Murga, Cristina
Insulin resistance (IR) and obesity are important risk factors for non-alcoholic fatty liver disease (NAFLD). G protein-coupled receptor kinase 2 (GRK2) is involved in the development of IR and obesity in vivo. However, its possible contribution to NAFLD and/or non-alcoholic steatohepatitis (NASH) independently of its role on IR or fat mass accretion has not been explored. Here, we used wild-type (WT) or GRK2 hemizygous (GRK2±) mice fed a high-fat diet (HFD) or a methionine and choline-deficient diet (MCD) as a model of NASH independent of adiposity and IR. GRK2± mice were protected from HFD-induced NAFLD. Moreover, MCD feeding caused an increased in triglyceride content and liver-to-body weight ratio in WT mice, features that were attenuated in GRK2± mice. According to their NAFLD activity score, MCD-fed GRK2± mice were diagnosed with simple steatosis and not overt NASH. They also showed reduced expression of lipogenic and lipid-uptake markers and less signs of inflammation in the liver. GRK2± mice preserved hepatic protective mechanisms as enhanced autophagy and mitochondrial fusion and biogenesis, together with reduced endoplasmic reticulum stress. GRK2 protein was increased in MCD-fed WT but not in GRK2± mice, and enhanced GRK2 expression potentiated palmitic acid-triggered lipid accumulation in human hepatocytes directly relating GRK2 levels to steatosis. GRK2 protein and mRNA levels were increased in human liver biopsies from simple steatosis or NASH patients in two different human cohorts. Our results describe a functional relationship between GRK2 levels and hepatic lipid accumulation and implicate GRK2 in the establishment and/or development of NASH., Ministerio de Economia y Competitividad (MINECO/FEDER), Spain (grants SAF2014-55511-R and SAF2017-84125-R to F.M and C. M., grant SAF2015-65267-R to A.M.V., grant SAF2016-76028R to L.F. and SAF2017-87301-R to M.L.M.-C); Comunidad de Madrid-B2017/BMD-3671-INFLAMUNE to F.M.; Gobierno Vasco-Departamento de Salud 2013111114 and EITB Maratoia BIO15/CA/014 (to M.L.M.C); European Foundation for the Study of Diabetes (EFSD) Novo Nordisk Partnership for Diabetes Research in Europe Grant (to F.M.); Asociacion Espanola contra el Cancer (M.L.M-C) and Fundacion Ramon Areces (to C.M.). Instituto de Salud Carlos III (with European FEDER contribution) funds CIBERCV (grant CB16/11/00278 to F.M), CIBERDEM and CIBERehd, Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Protein tyrosine phosphatase 1b deficiency protects against hepatic fibrosis by modulating nadph oxidases

  • García-Ruiz, Inmaculada
  • Blanes Ruiz, Nerea
  • Rada, Patricia
  • Pardo, Virginia
  • Ruiz, Laura
  • Blas-García, Ana
  • Valdecantos, M. P.
  • Grau Sanz, Montserrat
  • Solís-Herruzo, José A.
  • Valverde, Ángela M.
Inflammation is typically associated with the development of fibrosis, cirrhosis and hepatocellular carcinoma. The key role of protein tyrosine phosphatase 1B (PTP1B) in inflammatory responses has focused this study in understanding its implication in liver fibrosis. Here we show that hepatic PTP1B mRNA expression increased after bile duct ligation (BDL), while BDL-induced liver fibrosis was markedly reduced in mice lacking Ptpn1 (PTP1B−/−) as assessed by decreased collagen deposition and α-smooth muscle actin (α-SMA) expression. PTP1B−/− mice also showed a significant increase in mRNA levels of key markers of monocytes recruitment (Cd68, Adgre1 and Ccl2) compared to their wild-type (PTP1B+/+) littermates at early stages of injury after BDL. Interestingly, the lack of PTP1B strongly increased the NADPH oxidase (NOX) subunits Nox1/Nox4 ratio and downregulated Cybb expression after BDL, revealing a pro-survival pattern of NADPH oxidase induction in response to liver injury. Chimeric mice generated by transplantation of PTP1B−/− bone marrow (BM) into irradiated PTP1B+/+ mice revealed similar hepatic expression profile of NOX subunits than PTP1B−/− mice while these animals did not show differences in infiltration of myeloid cells at 7 days post-BDL, suggesting that PTP1B deletion in other liver cells is necessary for boosting the early inflammatory response to the BDL. PTP1B−/− BM transplantation into PTP1B+/+ mice also led to a blockade of TGF-β and α-SMA induction after BDL. In vitro experiments demonstrated that deficiency of PTP1B in hepatocytes protects against bile acid-induced apoptosis and abrogates hepatic stellate cells (HSC) activation, an effect ameliorated by NOX1 inhibition. In conclusion, our results have revealed that the lack of PTP1B switches NOX expression pattern in response to liver injury after BDL and reduces HSC activation and liver fibrosis., This work was funded by grants SAF2015-65267-R and RTI2018-094052-B-100 (MICINN/FEDER, Spain), S2017/BMD-3684 MOIR2-CM (Comunidad de Madrid, Spain) and CIBERdem (ISCIII, Spain) to A.M.V; IJCI-2014-19381 (MINECO/FEDER, Spain) to P.R and A.M.V. We also acknowledge H2020 Marie Sklodowska-Curie ITN-TREATMENT (Grant Agreement 721236, European Commission)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Modulation of microglia in the retina: new insights into diabetic retinopathy

  • Arroba, Ana I.
  • Valverde, Ángela M.
During last decades, the diagnosis of diabetes has been associated with several chronic complications such as diabetic retinopathy (DR). Recent studies of DR have revealed an inflammatory component, which precedes the detection of alterations in the visual function. During DR, the inflammatory process presents two opposite roles depending on the polarization of resident immune cells of the retina triggering proinflammatory (M1) or antiinflammatory (M2) actions. In an early stage of DR, the M2 response concurs with the M1 and is able to ameliorate inflammation and delay the progression of the disease. However, during the progression of DR, the M1 response is maintained whereas the M2 declines and, in this scenario, the classical proinflammatory signaling pathways are chronically activated leading to retinal neurodegeneration and the loss of visual function. The M1/M2 responses are closely related to the activation and polarization of microglial cells. This review aims to offer an overview of the recent insights into the role of microglial cells during inflammation in DR. We have focused on the possibility of modulating microglia polarization as a new therapeutic strategy in DR treatments., The research of A.M.V. laboratory has been supported by the Spanish Ministry of Economy and Competitivity (Grant SAF2015-65267-R MINECO/FEDER cofounded by the Fondos Europeos de Desarrollo Regional de la Unión Europea), Instituto de Salud Carlos III (Grant INFLAMES-PIE14/00045 and CIBERdem), and European Union (FP7 HEALTH.2011.2.4.3.1, EUROCONDOR Grant Agreement Number 278040). We acknowledge all EUROCONDOR partners for support and helpful discussions., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Somatostatin protects human retinal pericytes from inflammation mediated by microglia

  • Mazzeo, Aurora
  • Arroba, Ana I.
  • Beltramo, Elena
  • Valverde, Ángela M.
  • Porta, Massimo
Diabetic retinopathy (DR) is usually considered a microvascular disease. However, involvement of the neuroretina in the early stages of DR has recently gained major credit. Inflammatory processes, leading to glial activation and neuronal apoptosis, develop early in the retina of diabetic subjects. Pericytes constitute a link between the vascular and the neural retina, play a central role in blood-retinal barrier maintenance, and may influence neuroinflammation. Somatostatin (SST) is a potent neuroprotective factor, which is down-regulated during early DR. In this paper, we have investigated the effects of the inflammatory signals triggered by the activation of microglia on inflammation and apoptosis/survival pathways in pericytes. Microglia cells (Bv-2) were stimulated with lipopolysaccharide (LPS) and/or SST. Human retinal pericytes (HRP) were exposed to conditioned media (CM) collected from Bv-2 cells in physiological conditions and in the settings described above. A panel of inflammation, apoptosis and survival mediators was analyzed. HRP treated with LPS-CM showed a significant increase of pro-inflammatory (iNos and TNFα) and pro-apoptotic mediators (FasL, active caspase-8, tBid and Bax), and a concomitant decrease in pro-survival factors (BclxL and pAkt). SST added to LPS was able to counteract these effects in all conditions. In conclusion, SST is able to modulate apoptosis/survival pathways in HRP during microglia-mediated inflammation. These results demonstrate a crosstalk between microglia and retinal pericytes, evidencing a possible defensive role of microglia in the early phases of DR., This work was supported by the European Commission's Seventh Framework Programme (EUROCONDOR project, grant number 278040), the EFSD (EFSD-Albert Renold Travel Fellowship to AM), the MINECO/FEDER (Spain, grant number SAF2015-65267-R) and the CIBERdem (ISCIII, Spain)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Transcription factor NRF2 as a therapeutic target for chronic diseases: A systems medicine approach

  • Cuadrado, Antonio
  • Manda, Gina
  • Hassan, Ahmed
  • Alcaraz, María José
  • Barbas, Coral
  • Daiber, Andreas
  • Ghezzi, Pietro
  • León, Rafael
  • López, Manuela G.
  • Oliva, Baldo
  • Pajares, Marta
  • Rojo, Ana I.
  • Robledinos-Antón, Natalia
  • Valverde, Ángela M.
  • Guney, Emre
  • Schmidt, Harald H.H.W.
Systems medicine has a mechanism-based rather than a symptom- or organ-based approach to disease and identifies therapeutic targets in a nonhypothesis-driven manner. In this work, we apply this to transcription factor nuclear factor (erythroid-derived 2)-like 2 (NRF2) by cross-validating its position in a protein-protein interaction network (the NRF2 interactome) functionally linked to cytoprotection in low-grade stress, chronic inflammation, metabolic alterations, and reactive oxygen species formation. Multiscale network analysis of these molecular profiles suggests alterations of NRF2 expression and activity as a common mechanism in a subnetwork of diseases (the NRF2 diseasome). This network joins apparently heterogeneous phenotypes such as autoimmune, respiratory, digestive, cardiovascular, metabolic, and neurodegenerative diseases, along with cancer. Importantly, this approach matches and confirms in silico several applications for NRF2-modulating drugs validated in vivo at different phases of clinical development. Pharmacologically, their profile is as diverse as electrophilic dimethyl fumarate, synthetic triterpenoids like bardoxolone methyl and sulforaphane, protein-protein or DNA-protein interaction inhibitors, and even registered drugs such as metformin and statins, which activate NRF2 and may be repurposed for indications within the NRF2 cluster of disease phenotypes. Thus, NRF2 represents one of the first targets fully embraced by classic and systems medicine approaches to facilitate both drug development and drug repurposing by focusing on a set of disease phenotypes that appear to be mechanistically linked. The resulting NRF2 drugome may therefore rapidly advance several surprising clinical options for this subset of chronic diseases., This work was supported by Grants SAF2015-71304-REDT, SAF2016-76520-R, SAF2013-4874R, SAF2015-65267-R, and BIO2014-57518 of the Spanish Ministry of Economy and Competiveness; PII4/00372 from the Health Institute Carlos III; PROMETEOII/2014/071 of Generalitat Valenciana; P_37_732/2016 REDBRAIN of the European Regional Development Fund; Competitiveness Operational Program 2014-2020; and the ERC Advanced Grant RadMed 294683 and COST action 15120 OpenMultiMed (H.H.H.W.S.). M.P. is the recipient of a FPU fellowship of Autonomous University of Madrid. E.G. is supported by a European-cofunded Beatriu de Pinos fellowship. R.L. is supproted by the Miguel Servet II fellow (CPII16/00014)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

p38α deficiency restrains liver regeneration after partial hepatectomy triggering oxidative stress and liver injury

  • Rius-Pérez, Sergio
  • Tormos, Ana M.
  • Pérez, Salvador
  • Finamor, Isabela
  • Rada, Patricia
  • Valverde, Ángela M.
  • Nebreda, Ángel R.
  • Sastre, Juan
  • Taléns-Visconti, Raquel
p38α MAPK negatively regulates the G1/S and G2/M cell cycle transitions. However, liver-specific p38α deficiency impairs cytokinesis and reduces hepatocyte proliferation during cirrhosis and aging in mice. In this work, we have studied how p38α down-regulation affects hepatocyte proliferation after partial hepatectomy, focusing on mitotic progression, cytokinesis and oxidative stress. We found that p38α deficiency triggered up-regulation of cyclins A1, B1, B2, and D1 under basal conditions and after hepatectomy. Moreover, p38α-deficient hepatocytes showed enhanced binucleation and increased levels of phospho-histone H3 but impaired phosphorylation of MNK1 after hepatectomy. The recovery of liver mass was transiently delayed in mice with p38α-deficient hepatocytes vs wild type mice. We also found that p38α deficiency caused glutathione oxidation in the liver, increased plasma aminotransferases and lactate dehydrogenase activities, and decreased plasma protein levels after hepatectomy. Interestingly, p38α silencing in isolated hepatocytes markedly decreased phospho-MNK1 levels, and silencing of either p38α or Mnk1 enhanced binucleation of hepatocytes in culture. In conclusion, p38α deficiency impairs mitotic progression in hepatocytes and restrains the recovery of liver mass after partial hepatectomy. Our results also indicate that p38α regulates cytokinesis by activating MNK1 and redox modulation., A.M.T. was recipient of a fellowship from the Ministry of Economy and Competitiveness. This work was supported by Grants SAF 2015-71208-R with FEDER funds and CSD-2007-00020 from the Spanish Ministry of Economy and Competitiveness (MINECO, Spain, http://www.mineco.gob.es/portal/site/mineco/) and GV PROMETEO II 2014-056 from Generalitat Valenciana to J.S. and R.T.V., and by Grant SAF 2015- 65267-R (MINECO/FEDER) and by Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERdem, ISCIII, Spain) to A.M.V., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Contribución de congreso (ConferenceOutput)

Activation of brown adipose tissue (BAT) might play a major and beneficial role against insulin resistance associated to inflammation. Beneficial effects of modulating SIRT1 activity

  • Escalona-Garrido, Carmen
  • Vázquez Pérez, Patricia
  • García-Casarrubios, Ester
  • Obregón, María Jesús
  • Valverde, Ángela M.
Resumen del trabajo presentado al 1st PhD Research Symposium in Health Sciences and Biomedicine, celebrado en la Universidad Autónoma de Madrid el 18 de mayo de 2018., This study was supported by funding from project SAF 2015-65267-R., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Impact of global PTP1B deficiency on the gut barrier permeability during NASH in mice

  • Rubio, Carmen
  • Puerto, Marta
  • García-Rodríquez, Juan J.
  • Lu, Van B.
  • García Martínez, Irma
  • Alén, Rosa
  • Sanmartín-Salinas, Patricia
  • Toledo-Lobo, M. Val
  • Saiz, Jorge
  • Ruperez, Javier
  • Barbas, Coral
  • Menchén, Laura
  • Gribble, Fiona M.
  • Reimann, Frank
  • Guijarro, Luis M.
  • Carrascosa, José María
  • Valverde, Ángela M.
[Objective]: Non-alcoholic steatohepatitis (NASH) is characterized by a robust pro-inflammatory component at both hepatic and systemic levels together with a disease-specific gut microbiome signature. Protein tyrosine phosphatase 1 B (PTP1B) plays distinct roles in non-immune and immune cells, in the latter inhibiting pro-inflammatory signaling cascades. In this study, we have explored the role of PTP1B in the composition of gut microbiota and gut barrier dynamics in methionine and choline-deficient (MCD) diet-induced NASH in mice., [Methods]: Gut features and barrier permeability were characterized in wild-type (PTP1B WT) and PTP1B-deficient knockout (PTP1B KO) mice fed a chow or methionine/choline-deficient (MCD) diet for 4 weeks. The impact of inflammation was studied in intestinal epithelial and enteroendocrine cells. The secretion of GLP-1 was evaluated in primary colonic cultures and plasma of mice., [Results]: We found that a shift in the gut microbiota shape, disruption of gut barrier function, higher levels of serum bile acids, and decreased circulating glucagon-like peptide (GLP)-1 are features during NASH. Surprisingly, despite the pro-inflammatory phenotype of global PTP1B-deficient mice, they were partly protected against the alterations in gut microbiota composition during NASH and presented better gut barrier integrity and less permeability under this pathological condition. These effects concurred with higher colonic mucosal inflammation, decreased serum bile acids, and protection against the decrease in circulating GLP-1 levels during NASH compared with their WT counterparts together with increased expression of GLP-2-sensitive genes in the gut. At the molecular level, stimulation of enteroendocrine STC-1 cells with a pro-inflammatory conditioned medium (CM) from lipopolysaccharide (LPS)-stimulated macrophages triggered pro-inflammatory signaling cascades that were further exacerbated by a PTP1B inhibitor. Likewise, the pro-inflammatory CM induced GLP-1 secretion in primary colonic cultures, an effect augmented by PTP1B inhibition., [Conclusion]: Altogether our results have unraveled a potential role of PTP1B in the gut–liver axis during NASH, likely mediated by increased sensitivity to GLPs, with potential therapeutic value., This work was funded by grants SAF2015-65267-R (MINECO/FEDER, UE), RTI2018-094052-B-100 (MCI/AEI/FEDER, UE), S2010/BMD-2423, S2017/BMD-3684 (Comunidad de Madrid, Spain), CIBERdem, CIBERhed and PI 16/02096 (ISCIII, Spain). We also acknowledge grants H2020 Marie Sklodowska-Curie ITN-TREATMENT (Grant Agreement 721236, European Commission), Spanish Ministry of Education-MECD (FPU13/05802 grant to C.R) and Fundación Ramón Areces (to A.M.V.). CBMSO is recipient of institutional aid from Fundación Ramón Areces. VBL, FMG and FR received funding from a Wellcome Trust joint investigator award (106262/Z/14/Z and 106263/Z/14/Z) and a joint MRC programme within the Metabolic Diseases Unit (MRC_MC_UU_12012/3), United Kingdom. VBL received a project support grant from the Society for Endocrinology, United Kingdom. The MRL Histology and Biochemistry Assay Lab Core facilities received funding from the MRC Metabolic Diseases Unit [MRC_MC_UU_12012/5] and the Imaging Core through a Wellcome Trust Strategic Award [100574/Z/12/Z], United Kingdom., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Imbalance between pro-apoptotic and pro-survival factors in human retinal pericytes in diabetic-like conditions

  • Beltramo, Elena
  • Arroba, Ana I.
  • Mazzeo, Aurora
  • Valverde, Ángela M.
  • Porta, Massimo
[Purpose]: Loss of pericytes is one the key events in the pathogenesis of diabetic retinopathy. We have previously demonstrated that human retinal pericytes (HRP) are more vulnerable to intermittent than stable high glucose concentrations, with an increase in apoptosis. Our aim was to explore the expression of molecules involved in pro-apoptotic and survival pathways in pericytes cultured in stable/intermittent high glucose and/or hypoxia, to clarify the mechanisms of action of these diabetic-like stressing stimuli. [Methods]: Human retinal pericytes (HRP) were exposed intermittently at 48-hr intervals to high/physiological glucose for 8 days (intHG) and/or hypoxia over the last 48 hr. Control cells were kept in stable physiological and high glucose. Cell proliferation and apoptosis were assessed. The expression of pro-apoptotic and pro-survival molecules was evaluated by Western blotting. Caspase-8 translocation from the cytoplasm into the nucleus was checked by Western blotting of nuclear versus cytoplasmic fractions and immunofluorescence. [Results]: Hypoxia, alone and combined with intHG, increased HRP apoptosis and decreased proliferation. Pro-apoptotic molecules increased in HRP cultured in these conditions, while some survival markers decreased. Conversely, in stable HG, pro-apoptotic molecules were stable or even decreased, and survival factors increased. Translocation of caspase-8 from cytoplasm into nucleus indicates a primary role for this molecule in inducing apoptosis. [Conclusion]: Diabetic-like conditions are able to stimulate pericyte apoptosis through activation of pro-apoptotic molecules, leading to an imbalance between pro-apoptotic and survival signalling pathways, with caspase-8 playing a pivotal role. Our identification of such intermediates could help finding new therapeutic approaches for the prevention of diabetic retinopathy., This research was supported by the EUROCONDOR project, grant agreement number 278040, funded by the European Commission's Seventh Framework Programme (theme FP7-HEALTH-2011.2.4.3-1) and grant SAF2015-65267-R/FEDER (Ministerio de Economía y Competitividad, Spain).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Contribución de congreso (ConferenceOutput)

Modulation of SIRT1 by IL1b/NFkB signaling during acetaminophen-induced hepatotoxicity

  • Rada, Patricia
  • Pardo, Virginia
  • Mobasher, Maysa A.
  • García Martínez, Irma
  • Ruiz-Cañas, Laura
  • Sánchez-Ramos, Cristina
  • Alemany, Susana
  • Monsalve, María
  • Valverde, Ángela M.
Resumen del trabajo presentado al 5th Symposium on Biomedical Research: "Advances and Perspectives In Pharmacology, Drug Toxicity and Pharmacogenetics", celebrado en Madrid del 15 al 16 de marzo de 2018., [Introduction]: The liver is the main organ in charge of drug catabolism and also the major site susceptible to drug injury. Sirtuin 1 (SIRT1), a NAD+-dependent histone deacetylase, is a key player in liver physiology and a therapeutic target against hepatic inflammation. In this study, we evaluated the role of SIRT1 in the pro-inflammatory context and oxidative stress during acetaminophen (APAP)-mediated hepatotoxicity., [Material and Methods]: SIRT1 expression was analyzed in APAP-induced liver failure in humans and mice. Hepatotoxicity was assessed in wild-type and transgenic mice overexpressing SIRT1 (SIRT1 Tg) poisoned with APAP (300 mg/kg). Raw 264.7 and peritoneal macrophages were treated with APAP and conditioned medium (CM) was added to mouse hepatocytes. siRNA was used to reduce inflammatory mediators in hepatocytes., [Results]: SIRT1 protein levels decreased in human and mouse livers following APAP overdose. SIRT1-Tg mice maintained higher levels of SIRT1 upon APAP injection than wild-type mice and were protected against hepatotoxicity by modulation of antioxidant systems and restrained inflammatory responses, with decreased oxidative stress, pro-inflammatory cytokine mRNA levels, nuclear factor kappa B (NFκB) signaling, and cell death. Mouse hepatocytes stimulated with conditioned medium of APAP-treated macrophages (APAP-CM) showed decreased SIRT1 levels; an effect mimicked by interleukin 1β (IL1β), an activator of NFκB. This negative modulation was abolished by neutralizing IL1β in APAP-CM or silencing p65-NFκB in hepatocytes. APAP-CM of macrophages from SIRT1-Tg mice failed to downregulate SIRT1 protein levels in hepatocytes. In vivo administration of the NFκB inhibitor BAY 11-7082 preserved SIRT1 levels and protected from APAP-mediated hepatotoxicity., [Conclusion]: SIRT1 protein levels are downregulated by IL1β/NFκB signaling in APAP hepatotoxicity, resulting in inflammation and oxidative stress. Thus, maintenance of SIRT1 during APAP overdose by inhibiting NFκB might be clinically relevant. Our work evidenced the unique role of SIRT1 in APAP hepatoprotection by targeting oxidative stress and inflammation., This work was funded by SAF2015-65267-R (MINECO/FEDER), CIBERdem (ISCIII, Spain), INFLAMES (ISCIII PIE14/00045, co-funded by ERDF, “Investing in your future”) to A.M.V; IJCI-2014-19381 (MINECO/FEDER) to P.R and A.M.V; SAF2014-52009-R (MINECO/FEDER) to S.A; SAF2015-63904-R (MINECO/FEDER) to M.M.; CP14/00181 (ISCIII/FEDER) to A. G-R; PI13/00021 (ISCIII/FEDER) to J.M. CIBERehd (ISCIII, Spain) to A. G-R and J.M; Grant 37/371 from Al Jouf University (to M.A.M). We also acknowledge H2020 Marie Sklodowska-Curie ITN-TREATMENT (Grant Agreement number 721236) (European Commission).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Transcription factor NRF2 as a therapeutic target for chronic diseases: A systems medicine approach

  • Cuadrado, Antonio
  • Manda, Gina
  • Hassan, Ahmed
  • Alcaraz, María José
  • Barbas, Coral
  • Daiber, Andreas
  • Ghezzi, Pietro
  • León, Rafael
  • López, Manuela G.
  • Oliva Miguel, Baldomero
  • Pajares, Marta
  • Rojo, Ana I.
  • Robledinos Antón, Natalia
  • Valverde, Ángela María
  • Guney, Emre
  • Schmidt, Harald H.H.W.
Systems medicine has a mechanism-based rather than a symptom- or organ-based approach to disease and identifies therapeutic targets in a nonhypothesis-driven manner. In this work, we apply this to transcription factor nuclear factor (erythroid-derived 2)-like 2 (NRF2) by cross-validating its position in a protein-protein interaction network (the NRF2 interactome) functionally linked to cytoprotection in low-grade stress, chronic inflammation, metabolic alterations, and reactive oxygen species formation. Multiscale network analysis of these molecular profiles suggests alterations of NRF2 expression and activity as a common mechanism in a subnetwork of diseases (the NRF2 diseasome). This network joins apparently heterogeneous phenotypes such as autoimmune, respiratory, digestive, cardiovascular, metabolic, and neurodegenerative diseases, along with cancer. Importantly, this approach matches and confirms in silico several applications for NRF2-modulating drugs validated in vivo at different phases of clinical development. Pharmacologically, their profile is as diverse as electrophilic dimethyl fumarate, synthetic triterpenoids like bardoxolone methyl and sulforaphane, protein-protein or DNA-protein interaction inhibitors, and even registered drugs such as metformin and statins, which activate NRF2 and may be repurposed for indications within the NRF2 cluster of disease phenotypes. Thus, NRF2 represents one of the first targets fully embraced by classic and systems medicine approaches to facilitate both drug development and drug repurposing by focusing on a set of disease phenotypes that appear to be mechanistically linked. The resulting NRF2 drugome may therefore rapidly advance several surprising clinical options for this subset of chronic diseases., This work was supported by Grants SAF2015-71304-REDT, SAF2016-76520-R, SAF2013-4874R, SAF2015-65267-R, and BIO2014-57518 of the Spanish Ministry of Economy and Competiveness; PII4/00372 from the Health Institute Carlos III; PROMETEOII/2014/071 of Generalitat Valenciana; P_37_732/2016 REDBRAIN of the European Regional Development Fund; Competitiveness Operational Program 2014-2020; and the ERC Advanced Grant RadMed 294683 and COST action 15120 OpenMultiMed (H.H.H.W.S.). M.P. is the recipient of a FPU fellowship of Autonomous University of Madrid. E.G. is supported by a European-cofunded Beatriu de Pinos fellowship. R.L. is supproted by the Miguel Servet II fellow (CPII16/00014).
Docta Complutense
Publication Artículo científico (JournalArticle)

Dual role of protein tyrosine phosphatase 1B in the progression and reversion of non-alcoholic steatohepatitis

  • González-Rodríguez, Águeda
  • Valdecantos, M. Pilar
  • Rada, Patricia
  • Addante, Annalisa
  • Barahona, Inés
  • Rey, Esther
  • Pardo, Virginia
  • Ruiz, Laura
  • Laiglesia, Laura M.
  • Moreno-Aliaga, María J.
  • García-Monzón, Carmelo
  • Sánchez Muñoz, Aranzazu
  • Martínez Valverde, Ángela María
Objectives: Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in Western countries. Protein tyrosine phosphatase 1B (PTP1B), a negative modulator of insulin and cytokine signaling, is a therapeutic target for type 2 diabetes and obesity. We investigated the impact of PTP1B deficiency during NAFLD, particularly in non-alcoholic steatohepatitis (NASH). Methods: NASH features were evaluated in livers from wild-type (PTP1BWT) and PTP1B-deficient (PTP1BKO) mice fed methionine/cholinedeficient diet (MCD) for 8 weeks. A recovery model was established by replacing MCD to chow diet (CHD) for 2e7 days. Non-parenchymal liver cells (NPCs) were analyzed by flow cytometry. Oval cells markers were measured in human and mouse livers with NASH, and in oval cells from PTP1BWT and PTP1BKO mice. Results: PTP1BWT mice fed MCD for 8 weeks exhibited NASH, NPCs infiltration, and elevated Fgf21, Il6 and Il1b mRNAs. These parameters decreased after switching to CHD. PTP1B deficiency accelerated MCD-induced NASH. Conversely, after switching to CHD, PTP1BKO mice rapidly reverted NASH compared to PTP1BWT mice in parallel to the normalization of serum triglycerides (TG) levels. Among NPCs, a drop in cytotoxic natural killer T (NKT) subpopulation was detected in PTP1BKO livers during recovery, and in these conditions M2 macrophage markers were upregulated. Oval cells markers (EpCAM and cytokeratin 19) significantly increased during NASH only in PTP1B-deficient livers. HGF-mediated signaling and proliferative capacity were enhanced in PTP1BKO oval cells. In NASH patients, oval cells markers were also elevated. Conclusions: PTP1B elicits a dual role in NASH progression and reversion. Additionally, our results support a new role for PTP1B in oval cell proliferation during NAFLD.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Hepatic regulation of VLDL receptor by PPARβ/δ and FGF21 modulates non-alcoholic fatty liver disease

  • Zarei, Mohammad
  • Barroso, Emma
  • Palomer, Xavier
  • Dai, Jianli
  • Rada, Patricia
  • Quesada-López, Tania|||0000-0002-7818-4351
  • Escolà-Gil, Joan Carles|||0000-0001-9021-2485
  • Cedó, Lídia|||0000-0003-4354-3411
  • Zali, Mohammad Reza
  • Molaei, Mahsa
  • Dabiri, Reza
  • Vázquez, Santiago|||0000-0002-9296-6026
  • Pujol Bech, Eugenia|||0000-0003-1941-0539
  • Valverde, Ángela M.
  • Villarroya, Francesc|||0000-0003-1266-9142
  • Liu, Yong
  • Wahli, Walter
  • Vázquez-Carrera, Manuel
The very low-density lipoprotein receptor (VLDLR) plays an important role in the development of hepatic steatosis. In this study, we investigated the role of Peroxisome Proliferator-Activated Receptor (PPAR)β/δ and fibroblast growth factor 21 (FGF21) in hepatic VLDLR regulation. Studies were conducted in wild-type and Pparβ/δ -null mice, primary mouse hepatocytes, human Huh-7 hepatocytes, and liver biopsies from control subjects and patients with moderate and severe hepatic steatosis. Increased VLDLR levels were observed in liver of Pparβ/δ -null mice and in Pparβ/δ -knocked down mouse primary hepatocytes through mechanisms involving the heme-regulated eukaryotic translation initiation factor 2α (eIF2α) kinase (HRI), activating transcription factor (ATF) 4 and the oxidative stress-induced nuclear factor (erythroid-derived 2)-like 2 (Nrf2) pathways. Moreover, by using a neutralizing antibody against FGF21, Fgf21 -null mice and by treating mice with recombinant FGF21, we show that FGF21 may protect against hepatic steatosis by attenuating endoplasmic reticulum (ER) stress-induced VLDLR upregulation. Finally, in liver biopsies from patients with moderate and severe hepatic steatosis, we observed an increase in VLDLR levels that was accompanied by a reduction in PPARβ/δ mRNA abundance and DNA-binding activity compared with control subjects. Overall, these findings provide new mechanisms by which PPARβ/δ and FGF21 regulate VLDLR levels and influence hepatic steatosis development.